Markets:

Overview

News

Currencies

International

Treasuries

Indivior Plc ADR (OP:INVVY)

N/A UNCHANGED

Last Price Updated: 10:23 AM EDT, Jun 9, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Indivior Plc ADR

Indivior Reaches $102.5M Settlement To Resolve Antitrust Litigation ↗

June 05, 2023

Indivior PLC (OTCPK:INVVY) (OTCPK:IZQVF) (LSE: NDV), an addiction treatment company, announced that its subsidiary, Indivior Inc., has reached an agreement to resolve the claims brought by the...

Via Benzinga

Activist Investor Recommends Yelp Explore Sale, Micron Projects China Ban To Curb Revenues, Spruce Point Capital Raises Concerns About Perion Network's Financial Practices: Today's Top News ↗

May 23, 2023

Wall Street Journal

Via Benzinga

Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment ↗

May 23, 2023

The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older.

Via Benzinga

Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio ↗

March 03, 2023

Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by...

Via Benzinga

Indivior Targeting Listing On NASDAQ For The Spring Of 2023 ↗

December 07, 2022

Indivior PLC (OTCPK:INVVY) (LON:INDV) will hold a capital markets day on December 7th in New York City. The event will be hosted by Mark Crossley, CEO, along with members of the Indivior executive...

Via Benzinga

Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14 ↗

November 14, 2022

Reuters

Via Benzinga

Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals ↗

November 14, 2022

Via Benzinga

Hypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legalization ↗

August 17, 2022

The Community Anti-Drug Coalitions of America (CADCA), which is fighting against federal cannabis legalization, recently removed a page on its website disclosing its partners.

Via Benzinga

Indivior Positioned To Profit If Aelis Farma's Study Of Cannabis Use Disorder Succeeds ↗

June 01, 2022

Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD).

Via Benzinga

Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users ↗

April 11, 2022

Indivior PLC (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid,...

Via Benzinga

Cannabis Movers & Shakers: MedMen, IM Cannabis, Avicanna, Avant Brands ↗

January 13, 2022

MedMen's CRO Tracy McCourt Named President Of Emerald Village West Hollywood Cannabis retailer MedMen Enterprises Inc.

Via Benzinga

Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags ↗

January 13, 2022

The FDA warned patients and prescribers about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain....

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Indivior Plc ADR (OP:INVVY)

All News about Indivior Plc ADR

Starting at $3.75/week.

Subscribe Today